HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lung Transplant Outcomes Group Selected Research

Primary Graft Dysfunction

1/2018Quantitative Evidence for Revising the Definition of Primary Graft Dysfunction after Lung Transplant.
10/2017Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension.
4/2016The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia.
3/2016Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk.
2/2015Lung size mismatch and primary graft dysfunction after bilateral lung transplantation.
3/2014Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction.
2/2014Preoperative plasma club (clara) cell secretory protein levels are associated with primary graft dysfunction after lung transplantation.
3/2013Clinical risk factors for primary graft dysfunction after lung transplantation.
9/2012Variation in PTX3 is associated with primary graft dysfunction after lung transplantation.
1/2012Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lung Transplant Outcomes Group Research Topics

Disease

19Primary Graft Dysfunction
01/2018 - 11/2007
5Idiopathic Pulmonary Fibrosis
09/2012 - 04/2011
4Acute Lung Injury
01/2018 - 11/2007
4Chronic Obstructive Pulmonary Disease (COPD)
02/2015 - 08/2011
3Lung Injury
01/2018 - 02/2014
3Pulmonary Arterial Hypertension
10/2017 - 04/2011
2Lung Diseases (Lung Disease)
10/2017 - 09/2012
2Pulmonary Hypertension
10/2017 - 08/2011
2Obesity
02/2014 - 11/2011
1Hyperoxia
04/2016
1Pulmonary Fibrosis (Fibrosing Alveolitis)
02/2014
1Overweight
03/2013
1Sarcoidosis (Schaumann Disease)
03/2013
1Reperfusion Injury
11/2011
1Cystic Fibrosis (Mucoviscidosis)
08/2011
1Pulmonary Edema
11/2007

Drug/Important Bio-Agent (IBA)

17Prostaglandins DIBA
01/2018 - 11/2007
4Biomarkers (Surrogate Marker)IBA
01/2018 - 02/2014
2SmokeIBA
10/2017 - 04/2016
2Oxygen (Dioxygen)IBA
10/2017 - 04/2016
2UteroglobinIBA
02/2014 - 03/2011
1CreatinineIBA
10/2017
1Plasminogen Activators (Plasminogen Activator)IBA
03/2016
1Proteins (Proteins, Gene)FDA Link
03/2016
1prostaglandin D3IBA
02/2015
1Dinoprostone (PGE2)FDA Link
03/2014
1Angiopoietin-2IBA
01/2012
1LeptinIBA
11/2011
1AdiponectinIBA
11/2011
1ResistinIBA
11/2011
1AdipokinesIBA
11/2011
1Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA
08/2011
1Receptor for Advanced Glycation End ProductsIBA
11/2009
1P-SelectinIBA
07/2009
1CytokinesIBA
02/2009
1ChemokinesIBA
02/2009
1Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
11/2007
1von Willebrand FactorIBA
11/2007

Therapy/Procedure

17Lung Transplantation
01/2018 - 11/2007
4Cardiopulmonary Bypass (Heart-Lung Bypass)
10/2017 - 11/2011
3Transplantation
10/2017 - 11/2011
1Blood Transfusion (Blood Transfusions)
11/2009